MacroGenics, Inc. Appoints New Senior Vice President of Clinical Development
ROCKVILLE, Md., Jan. 7 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Dr. Anastasia Daifotis as Senior Vice President, Clinical Development. "We are very fortunate to attract another exceptionally talented professional to the management team at MacroGenics," said Dr. Scott Koenig, President and CEO. "Anastasia's impressive clinical development experience combined with her senior leadership skills will complement our management team's expertise as we broaden and advance our pipeline towards commercialization."
Prior to joining Merck, Dr. Daifotis completed her general medical training at Mount Sinai Medical Center and was a Postdoctoral Research Fellow in Endocrinology at the Yale University School of Medicine. While there, she studied the regulation of parathyroid-hormone-related gene in normal tissue. She holds an M.D. from Albany Medical College and a B.A. from Princeton University.
About MacroGenics, Inc.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.
CONTACT: Scott Koenig, M.D., Ph.D., President and CEO, or Jim Karrels,
Vice President, CFO, both of MacroGenics, Inc., +1-301-251-5172,
info@macrogenics.com
Web site: http://www.macrogenics.com/